
==== Front
Lipids Health Dis
Lipids Health Dis
Lipids in Health and Disease
1476-511X
BioMed Central London

2273
10.1186/s12944-024-02273-z
Research
The U -shape relationship between free fatty acid level and adverse outcomes in coronary artery disease patients with hypertension: evidence from a large prospective cohort study
Wu Ting-Ting 123
Pan Ying 123
Zheng Ying-Ying 123
Wang Zhi-Long 123
Deng Chang-Jiang 123
Wang Shun 123
http://orcid.org/0000-0002-0632-4626
Xie Xiang xiangxie999@sina.com

123
1 grid.13394.3c 0000 0004 1799 3993 Department of Cardiology, Xinjiang Medical University Affiliated First Hospital, No. 137, Liyushan Road, Urumqi, 830054 China
2 grid.13394.3c 0000 0004 1799 3993 Key Laboratory of High Incidence Disease Research in Xingjiang, (Xinjiang Medical University, Ministry of Education), Urumqi, China
3 grid.13394.3c 0000 0004 1799 3993 Key Laboratory of Hypertension Research of Xinjiang Medical University, No. 137, Liyushan Road, Urumqi, 830054 China
10 9 2024
10 9 2024
2024
23 29118 5 2024
27 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Background

Evidence is scarce on the effect of free fatty acid (FFA) level in the prognosis of coronary artery disease (CAD) patients with hypertension. This study.

Methods

A large prospective cohort study with a follow-up period of average 2 years was conducted at Xinjiang Medical University Affiliated First Hospital from December 2016 to October 2021. A total of 10,395 CAD participants were divided into groups based on FFA concentration and hypertension status, and then primary outcome mortality and secondary endpoint ischemic events were assessed in the different groups.

Results

A total of 222 all-cause mortality (ACMs), 164 cardiac mortality (CMs), 718 major adverse cardiovascular events (MACEs) and 803 major adverse cardiovascular and cerebrovascular events (MACCEs) were recorded during follow-up period. A nonlinear relationship between FFA and adverse outcomes was observed only in CAD patients with hypertension. Namely, a “U -shape” relationship between FFA levels and long-term outcomes was found in CAD patients with hypertension. Lower FFA level (< 310 µmol/L), or higher FFA level (≥ 580 µmol/L) at baseline is independent risk factors for adverse outcomes. After adjustment for confounders, excess FFA increases mortality (ACM, HR = 1.957, 95%CI(1.240–3.087), P = 0.004; CM, HR = 2.704, 95%CI(1.495–4.890, P = 0.001) and MACE (HR = 1.411, 95%CI(1.077–1.848), P = 0.012), MACCE (HR = 1.299, 95%CI (1.013–1.666), P = 0.040) prevalence. Low levels of FFA at baseline can also increase the incidence of MACE (HR = 1.567,95%CI (1.187–2.069), P = 0.002) and MACCE (HR = 1.387, 95%CI (1.070–1.798), P = 0.013).

Conclusions

Baseline FFA concentrations significantly associated with long-term mortality and ischemic events could be a better and novel risk biomarker for prognosis prediction in CAD patients with hypertension.

Trial registration

The details of the design were registered on https://www.chictr.org.cn/ (Identifier NCT05174143).

Supplementary Information

The online version contains supplementary material available at 10.1186/s12944-024-02273-z.

Key messages

What is known on this topic?

• Free fatty acid (FFA) plays an essential role in hepatic triglyceride synthesis . Several studies have shown that plasma FFA concentration is a modifiable risk factor for metabolic disease. However, no evidence is currently available regarding the link between FFA and prognosis in CAD patients with hypertension.

What does this paper add?

• We observed a “U -shape” relationship between FFA and adverse outcomes in CAD patients with hypertension, which address a novel knowledge gap in the risk classification of CAD patients with hypertension.

Supplementary Information

The online version contains supplementary material available at 10.1186/s12944-024-02273-z.

Keywords

Free fatty acid
Adverse outcomes
Hypertension
Coronary artery disease
http://dx.doi.org/10.13039/501100001809 National Natural Science Foundation of China 82360097 Tianshan Talent, Xinjiang Science and Technology Project2022TSYCLJ0029 Key research and development projects of Xinjiang Province, China2022B03022-5 issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcIntroduction

As a major public health concern, hypertension is a leading cause of disability and mortality all over the world and imposes a heavy burden on health-care costs [1, 2]. However, the level of awareness, treatment and control of hypertension worldwide is overwhelmingly low [3]. Patients with coronary heart disease often suffer from high blood pressure. Evidence suggests that controlling blood pressure can help improve the prognosis of coronary artery disease (CAD) patients with hypertensive patients [4, 5]. Therefore, it is paramount to identify the risk factors to develop effective strategies to prevent or delay poor prognosis in CAD patients with hypertension.

Free fatty acid (FFA), also known as non-esterified fatty acid (NEFA), plays an essential role in hepatic triglyceride synthesis [6]. Several studies have shown that plasma FFA concentration is a modifiable risk factor for metabolic disease [7]. Its elevation has been observed in type 2 diabetes mellitus (T2DM), obesity, non-alcoholic fatty liver disease (NAFLD), poor myocardial function and related comorbidities [8–10]. Some researchers emphasize that elevated FFA is associated with the occurrence, development and poor prognosis of CAD [11, 12]. Evidence from the Paris prospective study proposes that FFA concentration could predict cancer mortality [13]. Pilz’s work on FFA indicates that higher FFA is independently associated with the elevated risk for all-cause mortality (ACM) and cardiac death [14, 15]. Noteworthy, our previous study identified that both low and elevated FFA levels were related with the adverse outcomes in CAD patients with T2DM [16]. However, no evidence is currently available regarding the link between FFA and prognosis in CAD patients with hypertension. With this background and our large cohort data, this study was designed to investigate the impact of FFA concentration on adverse outcomes in CAD patients with hypertension.

Methods

Study design

The design of the PRACTICE study has been reported previously [16]. Briefly, this analysis was performed within the PRACTICE study, which is a population-based, prospective cohort. At baseline, 15,250 CAD patients were recruited between 2016 and 2021 and have continued to be followed up. The study protocol was approved by the ethics committee of Xinjiang Medical University First Affiliated Hospital. Informed consent was provided by all participants. Individuals were included in this study if they had at least one significant coronary artery stenosis of ≥ 70% lumen diameter or a ≥ 50% stenosis of the left main, as shown by coronary angiography. Exclusion criteria were unavailable FFA data, severe infections, cancer, malignant liver, gallbladder and kidney disease, and blood disorders. The other exclusion criteria was described previously [16]. Finally, data from 10,395 CAD patients were analyzed. In this study, we divided all participants into four groups according to the quartiles of FFA concentration: quartile I (< 310 µmol/L), quartile II (310–420 µmol/L), quartile III ( 420–580 µmol/L), and quartile IV (≥ 580 µmol/L). Then we analyzed data of individuals with different blood pressure (BP) conditions to examine the influence of FFA in the adverse clinical outcomes of CAD patients with hypertension. Figure 1 shows a flowchart of the study.

Fig. 1 Flowchart of the PRACTICE study. CAD, Coronary artery disease; FFA, Free Fatty Acids

We also obtained demographic characteristics at admission, including age, sex, smoking status, alcohol use, and diabetes history. Hypertension was identified as systolic blood pressure (SBP) ≥ 140 mmHg and/or diastolic blood pressure (DBP) ≥ 90 mmHg at three times on different days or taking antihypertensive drugs [17]. Diabetes mellitus was diagnosed if patients with fasting blood glucose (FBG) ≥ 7.1 mmol/L, or 2 h post-load glucose ≥ 11.1 mmol/L, having a clear history of diabetes or using hypoglycaemic agents [18]. The medication was obtained from medication records. Haematological and biochemical data were tested using chemical analysis equipment (Dimension AR/AVL Clinical Chemistry System, Newark, NJ, USA) after patients fasted for at least 12 h in the Clinical Laboratory Department of the First Affiliated Hospital of Xinjiang Medical University.

The measurement of FFA

Serum samples were collected, separated and stored at − 80 °C after patients fasted for at least 12 h. Samples were incubated for 15 min at room temperature and then the concentration of FFA was measured using enzymatic colorimetry assay in the Clinical Laboratory Department of the First Affiliated Hospital of Xinjiang Medical University. The reference range of FFA concentration is 100–900 µmol/L, as described by the manufacturer.

Endpoints

The primary endpoints were all-cause mortality (ACM) and cardiac mortality (CM). The secondary endpoints were ischemic events including major adverse cardiovascular and cerebrovascular events (MACCE) and major adverse cardiovascular events (MACE). MACE consists of cardiac death, nonfatal heart attack, and revascularization. MACCE incorporates MACE plus stroke.

Follow-up

Patients were followed up after discharge at the end of 1 month, 3 months, 6 months, 1 year, 3 years and 5 years. At each visit, structured interviews were conducted to obtain self-reported information on clinical outcomes through clinical visits, telephone calls and questionnaires. An independent endpoint adjudication committee evaluated all events.

Statistical analyses

All statistical analyses were performed using SPSS 26.0 (SPSS Inc., Chicago, IL, USA) and R (version 4.0.3). We used proportions for qualitative data and means (SD) or median (IQR) for quantitative data to describe the baseline characteristics of the study cohort. We performed a χ² test to compare categorical variables. The unpaired t-test was used for normally distributed data, and the Mann-Whitney U test was used for non-normally distributed data. We analyze all time-to-event distributions.The Kaplan-Meier’s method (K-M) was used to analyse all time-to-event distributions, and the log-rank test was used to evaluate differences. We calculated hazard ratios (HRs) and 95% CIs for adverse outcomes by Cox proportional-hazards regression models adjusting for history of smoking, alcohol use, hypertension, diabetes, sex, age, heart rate, UA, Cr, TGs, TC, HDL-C, LDL-C, EF and medication use. We also plotted restricted cubic spline (RCS) to further evaluate the non-linear association, using log [FFA (umol/L)]. For all analyses, a P value of < 0.05 based 2-sided test is considered statistically significant.

Results

The 10,395 CAD participants were divided into 4 groups based on the quartile of FFA concentration. There were 7262 individuals with hypertension (Q1: n = 1650, Q2: n = 1723, Q3: n = 1896, Q4: n = 1993) and 3133 without hypertension (Q1: n = 926, Q2: n = 708, Q3: n = 801, Q4: n = 698). As shown in Table 1, some baseline characteristics vary significantly among different FFA groups in individuals with hypertension.The participants in Q4 quartile tend to be with a higher prevalence of TC, HDL-C, LDL-C, TB (total bilirubin) and TP (total protein) and a lower level of EF. The baseline characteristics for all patients and individuals without hypertension are shown in supplementary material (See supplementary material Table S1 and S2). Table 2 describes the clinical outcomes of individuals with or without hypertension. Over a median follow-up of 24 months, a total of 168 ACMs, 121 cm, 536 MACEs, and 603 MACCEs were recorded in individuals with hypertension during the follow-up period. The incidence of ACMs, CMs, MACEs and MACCEs was significantly different among four groups in individuals with hypertension [ACMs (P < 0.001), CMs (P < 0.001), MACEs (P = 0.001), and MACCEs (P = 0.008)]. In individuals without hypertension, only the incidence of ACMs and CMs was significantly different among four groups [ACMs (P < 0.006) and CMs (P < 0.033)]. Additionally, the incidence of MACEs and MACCEs in individuals with hypertension was significantly higher than those without hypertension, non significant in ACMs nor in CMs (Fig. 2). Kaplan–Meier survival analysis suggested that patients with high FFA or low FFA exhibited increased accumulated risk of poor outcomes (Fig. 3).

Table 1 Basic characteristics of participants with hypertension (n = 7262)

Variables	Q1	Q2	Q3	Q4	
(< 310 µmol/L)	(310–420 µmol/L)	(420–580 µmol/L)	(≥ 580 µmol/L)	
Female, n (%)	479(29.0)	479(27.8)	537(28.3)	596(29.9)	
Smoking, n (%)	609(36.9)	633(36.7)	719(37.9)	701(35.2)	
Alcohol use, n (%)	375(22.7)	426(24.7)	463(24.4)	476(23.9)	
Diabetes, n (%)	654(39.6)	719(41.7)	853(45.0)	1084(54.4)	
Age, years	60.7 ± 10.6	60.8 ± 10.8	61.0 ± 11.1	61.0 ± 11.6	
SBP, mmHg	134.0 ± 18.8	133.9 ± 18.8	134.3 ± 19.1	134.6 ± 18.8	
DBP, mmHg	78.8 ± 13.1	78.7 ± 13.3	79.9 ± 13.3	80.4 ± 13.5	
HR, beats/min	76.2 ± 11.1	76.9 ± 11.9	77.1 ± 11.9	78.4 ± 12.1	
Cr, µmol/L	69.0[59.0-80.7]	70.0[60.0–82.0]	59.2[71.0–83.0]	75.0[63.0–89.0]	
UA, mmol/L	330.0[272.8–393.0]	339.5[286.0-416.0]	341.0[283.8–411.0]	350.0[292.8-432.4]	
TG, mmol/L	1.3[1.0-1.8]	1.5[1.1-2.0]	1.5[1.1–2.1]	1.6[1.2–2.4]	
TC, mmol/L	3.7 ± 1.0	3.8 ± 1.0	3.9 ± 1.1	4.1 ± 1.2	
HDL-C, mmol/L	1.1 ± 0.3	1.1 ± 0.3	1.1 ± 0.3	1.2 ± 0.3	
LDL-C, mmol/L	2.3 ± 0.9	2.4 ± 0.8	2.5 ± 0.9	2.6 ± 0.9	
TB, µmol/L	66.7[63.3–70.6]	67.1[64.0-71.1]	67.6[64.2–71.3]	68.4[64.8–72.6]	
TP, g/L	67.1 ± 5.4	67.7 ± 5.5	67.9 ± 5.5	68.7 ± 5.8	
EF, %	61.1 ± 6.9	61.5 ± 6.8	61.2 ± 7.2	60.3 ± 8.1	
FBG, mmol/L	6.2 ± 2.2	6.3 ± 2.4	6.5 ± 2.5	7.1 ± 3.0	
GSP, mmol/L	2.2 ± 0.5	2.3 ± 0.4	2.3 ± 0.5	2.4 ± 0.5	
HbA1c, mmol/L	6.6 ± 1.5	6.5 ± 1.3	6.6 ± 1.4	6.9 ± 1.6	
ARB or ACEI, n (%)	830(50.3)	819(47.5)	969(51.1)	1029(51.6)	
β-Blockers, n (%)	941(59.6)	981(59.5)	1092(59.5)	1150(60.1)	
CCB, n (%)	465(29.5)	511(31.0)	573(31.2)	605(31.6)	
Aspirin, n (%)	1599(96.9)	1686(97.9)	1847(97.4)	1919(96.3)	
Statins, n (%)	1568(95.0)	1623(94.2)	1775(93.6)	1833(92.0)	
clopidogrel, n (%)	854(51.8)	879(51.0)	971(51.2)	1000(50.2)	
Note: To describe the baseline characteristics of the study cohort, proportions was used for qualitative data and means (SD) or median (IQR) was used for quantitative data. SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; Cr, creatinine; UA, uric acid; TG, total triglycerides; TC, total cholesterol; HDL-C, high-density lipoprotein-C; LDL-C, low-density lipoprotein-C; TB, total bilirubin; TP, total protein; EF, ejection fraction; FBG, Fasting blood glucose; GSP, Glycosylated serum protein; ARB, angiotensin receptor blocker; ACEI, angiotensin-converting enzyme inhibitor; CCB, calcium channel blockers

Table 2 Clinical outcomes of participants

Variables	Q1	Q2	Q3	Q4	x2	P value	
(< 310 µmol/L)	(310–420 µmol/L)	(420–580 µmol/L)	(≥ 580 µmol/L)	
CAD patients with hypertension (n = 7262)	
ACM, n (%)	31(1.9)	29(1.7)	32(1.7)	76(3.8)	27.533	< 0.001	
CM, n (%)	24(1.5)	21(1.2)	17(0.9)	59(3.0)	29.782	< 0.001	
MACE, n (%)	142(8.6)	114(6.6)	109(5.7)	171(8.6)	16.675	0.001	
MACCE, n (%)	151(9.2)	129(7.5)	132(7.0)	191(9.6)	11.837	0.008	
CAD patients without hypertension (n = 3133)	
ACM, n (%)	12(1.3)	6(0.8)	14(1.7)	22(3.2)	12.617	0.006	
CM, n (%)	10(1.1)	5(0.7)	11(1.4)	17(2.4)	8.734	0.033	
MACE, n (%)	63(6.8)	35(4.9)	47(5.9)	37(5.3)	2.977	0.395	
MACCE, n (%)	66(7.1)	41(5.8)	50(6.2)	43(6.2)	1.358	0.715	
Note: A χ² test was performed to compare categorical variables. A P value of < 0.05 based 2-sided test is considered statistically significant. ACM, all-cause mortality; CM, cardiac mortality; MACE, major adverse cardiovascular events; MACCE, major adverse cardiovascular and cerebrovascular events

Fig. 2 The comparison of clinical outcomes between hypertensive and non-hypertensive patients. ACM, all-cause mortality; CM, cardiac mortality; MACE, major adverse cardiovascular events; MACCE, major adverse cardiac and cerebrovascular events

Fig. 3 Cumulative Kaplan-Meier estimates of the time to the occurrence of clinical outcomes in patients according to four FFA categories under different hypertension status. ACM, all-cause mortality; CM, cardiac mortality; MACE, major adverse cardiovascular events; MACCE, major adverse cardiac and cerebrovascular events

Then, we calculated HRs and 95% CIs for adverse outcomes by Cox proportional-hazards regression models adjusting for history of smoking, alcohol use, hypertension, diabetes, sex, age, heart rate, UA, Cr, TGs, TC, HDL-C, LDL-C, EF and medication use. Among individuals with hypertension, both Q4 group and Q1 group had a higher incidence of ACM, CM, MACE and MACCE, compared with Q3 group (Ps < 0.05, Fig. 4). As shown in Table 3, compared with Q3, the incidence of ACM (adjusted HR = 1.957(1.240–3.087), P = 0.004) and CM (adjusted HR = 2.704(1.495–4.890), P = 0.001) in Q4 group was increased 0.957 times and 1.704 times, respectively. Moreover, using Q3 as reference, individuals in Q1 and Q4 both had higher risk of MACE (Q1: adjusted HR = 1.567(1.187–2.069), P = 0.002; Q4: adjusted HR = 1.411(1.077–1.848), P = 0.012) and MACCE (Q1: adjusted HR = 1.387(1.070–1.798), P = 0.013; Q4: adjusted HR = 1.299 (1.013–1.666), P = 0.040).

Fig. 4 The clinical outcome of CAD patients with hypertension. ACM, all-cause mortality; CM, cardiac mortality; MACE, major adverse cardiovascular events; MACCE, major adverse cardiac and cerebrovascular events

Table 3 Association between FFA levels and adverse outcomes

Variables	Q1	Q2	Q3	Q4	
HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value	
CAD patients with hypertension (n = 7262)	
ACM	1.138(0.667–1.944)	0.635	1.074(0.626–1.842)	0.795	Ref	/	1.957(1.240–3.087)	0.004	
CM	1.686(0.867–3.279)	0.124	1.468(0.741–2.907)	0.271	Ref	/	2.704(1.495–4.890)	0.001	
MACE	1.567(1.187–2.069)	0.002	1.293(0.970–1.724)	0.079	Ref	/	1.411(1.077–1.848)	0.012	
MACCE	1.387(1.070–1.798)	0.013	1.163(0.890–1.520)	0.270	Ref	/	1.299(1.013–1.666)	0.040	
CAD patients without hypertension (n = 3133)	
ACM	1.338(0.535–3.344)	0.534	0.363(0.096–1.372)	0.135	Ref	/	1.802(0.800-4.059)	0.155	
CM	1.327(0.471–3.740)	0.593	0.348(0.072–1.679)	0.189	Ref	/	1.734(0.692–4.344)	0.240	
MACE	1.258(0.820–1.931)	0.293	0.804(0.493–1.310)	0.380	Ref	/	0.851(0.528–1.373)	0.508	
MACCE	1.217(0.805–1.841)	0.352	0.857(0.540–1.362)	0.515	Ref	/	0.926(0.590–1.455)	0.740	
Note: a. Adjusting for history of smoking, alcohol use, hypertension, diabetes, sex, age, heart rate, UA, Cr, TGs, TC, HDL-C, LDL-C, EF and medication use; b, Using Q3 as reference. C, A P value of < 0.05 based 2-sided test is considered statistically significant. ACM, all-cause mortality; CM, cardiac mortality; MACE, major adverse cardiovascular events; MACCE, major adverse cardiovascular and cerebrovascular events

As Fig. 5 shown, RCS was plotted to present the nonlinear U-shaped relationship between FFA concentrations and mortality (ACM and CM) or ischemic events (MACE and MACCE).

Fig. 5 Restricted cubic spline plots for mortality and ischemic events according to FFA on a continuous scale. ACM, all-cause mortality; CM, cardiac mortality; MACE, major adverse cardiovascular events; MACCE, major adverse cardiac and cerebrovascular events

Discussion

The present analysis, from a well-designed prospective cohort of a large sample population, reports the nonlinear relationship between FFA concentration and the prognosis of CAD patients with hypertension. That is to say, when subjects with lower (< 310 µmol/L), or higher FFA level (≥ 580 µmol/L) at baseline were more easy to suffer from adverse outcomes. This “U-shape” relationship between FFA and poor prognosis in CAD patients with hypertension addresses a novel knowledge gap in risk classification.

Consistenting with previous conclusions [13–15], we found that hypertensive patients with high levels of FFA on admission are more likely to experience ischemic events among CAD group. Given that hypertension and certain lipid components have detrimental effects on clinical outcomes in cardiovascular disease patients [19–21], effectively managing relevant risk factors can improve the prognosis of CAD. As an important component of blood lipids, it is essential to further understand the role of FFA in CAD patients with hypertension. Previous studies have indicated that increased FFA concentration is associated with hypertension [22–24]. Magda M.I et al. conducted a study among white participants and found that baseline FFA was significantly higher in abdominally obese hypertensive subjects than in lean non-hypertensive individuals [22]. Similar results were reported by Bm E et al., who observed higher FFA concentration and turnover in obese hypertensive individuals compared to lean or obese normotensive individuals. They suggested that increased FFA plays an important role in elevating blood pressure [23].In the Paris Prospective Study included 2968 Caucasian men, baseline FFA was identified as a risk factor for hypertension (hazard rate ratio [RR] = 1.58, 95% confidence interval [CI] : 1.30–1.91] over 3 years of follow-up after controlling for possible confounding factors [24]. It may call for clinicians to pay more attention to FFA during lipid-lowering therapy in CAD patients with hypertension. Furthermore, we have innovatively discovered a “U-shaped” relationship between FFA and adverse outcomes in CAD patients with hypertension. This means that lower levels of FFA are also associated with poor prognosis in CAD patients with hypertension. It is worth exploring the intrinsic relationship and pathogenic mechanisms between low FFA levels and poor outcomes in CAD patients with hypertension. The study conducted by Tabara Y et al. demonstrated an inverse association between the augmentation index (AIx), a marker of central blood pressure, and quartiles of free fatty acids (FFA), namely with higher AIx observed in lower FFA quartiles [25]. Previous reports have indicated that elevated AIx is a risk factor for hypertension and cardiovascular disease [26, 27]. Therefore, it is plausible to suggest that low levels of FFA may exert reverse-regulatory effects on blood pressure through the elevation of AIx, potentially contributing to an unfavorable prognosis in hypertensive patients with coronary artery disease (CAD).

Given the intricate nature of biological systems, it is likely that additional mechanisms are at play. Studies have shown that the concentration of FFA in the blood increases when body is in a pathological state of T2DM or glycogen accumulation disease [28]. In this study, we similarly find an increase in FFA levels accompanied by a mild increase in FBG and HbA1c. The elevation of blood glucose and FFA can jointly lead to a large amount of reactive oxygen species (ROS) generation and oxidative stress, and at the same time cause a cascade of activation of multiple serine kinases, which in turn aggravates insulin resistance [29–31]. When insulin resistance increases, compensatory insulin secretion decreases, or both, the progression of diabetes is accelerated [32, 33]. This is consistent with our findings that the prevalence of diabetes in the high FFA group was observed to be higher, compared to that in the low group. Additionally, previous studies have shown that insulin resistance is associated with the pathogenesis of hypertension [34]. Therefore, it is reasonable to assume that the cross-linking of insulin resistance and FFA plays an important propulsive role in the development of malignant cardiovascular events. Furthermore, FFA actively promotes insulin resistance through macrophage activation and subsequent release of related cytokines, ultimately leading to endothelial dysfunction and vascular stiffness [35–38]. Considering arterial stiffness’ independent status as a risk factor for adverse cardiovascular events and the bidirectional causality between blood pressure and arterial stiffness, there may be synergy leading to an accelerated occurrence of adverse events [39, 40]. Additionally, FFA can impact established blood pressure regulatory systems such as the renin-angiotensin-aldosterone axis and the volume-vasopressin loop [7, 41]. FFA also has the potential to activate a1-adrenergic receptors, leading to heightened heart rate and blood vessel constriction, ultimately raising blood pressure [42]. Furthermore, elevated FFA levels in hepatocytes can result in increased production of ROS and endoplasmic reticulum (ER) stress [42, 43]. Potentially disrupting cellular metabolism due to excessive accumulation of FFA in the myocardium, leading to cellular dysfunction and death [44]. In summary, inappropriate FFA levels may exacerbate hypertension-related impairment, potentially contributing to a higher incidence of major adverse cardiovascular events (MACEs) and major adverse cardiac and cerebrovascular events (MACCEs) in individuals with hypertension compared to those without. Further research is necessary to confirm the significant role of FFA and hypertension in driving worse outcomes through these pathogenic pathways.

Limitations and strengths

This study should be interpreted with several limitations. First, we performed the analysis based on the baseline total FFA data without evaluating the FFA subclasses and their dynamic variants. Second, several metabolic factors and parameters, including insulin, diet, inflammation, oxygenated derivatives of FFA, and neural system activity, were not assessed in our analysis. Third, the participants in this analysis are all from a single cohort, and the exact cutoff used to define the FFA is likely to vary across cohorts. The strengths of this study include its large sample size, prospective study design, and longest follow-up duration.

Conclusions

We found a non-linear association between FFA concentration and hypertension in CAD patients, with an increased risk of poor long-term outcomes at reduced or increased FFA concentration, which should be further assessed.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1

Abbreviations

FFA Free Fatty Acids

CAD Coronary artery disease

ACM All-cause mortality

CM Cardiac mortality

MACCE Major adverse cardiac and cerebrovascular events

MACE Major adverse cardiovascular events

PRACTICE Personalized Antiplatelet Therapy According to CYP2C19 Genotype in Coronary Artery Disease

Acknowledgements

The authors acknowledged all nurses and doctors in the Heart Centre of Xinjiang Medical University Affiliated First Hospital. In addition, we acknowledged all patients of blood samples.

Author contributions

TTW and YP drafted the manuscript. YYZ and ZLW performed the statistical analysis. CJD and SW interpreted the data and prepared Figs. 1, 2, 3, 4 and 5. XX made substantial contributions to the critical revision, study conception and design. All authors reviewed and approved the final manuscript.

Funding

This work was supported by the National Natural Science Foundation of China (grant No. 82360097), Tianshan Talent, Xinjiang Science and Technology Project (2022TSYCLJ0029) and Key research and development projects of Xinjiang Province, China (2022B03022-5).

Data availability

No datasets were generated or analysed during the current study.

Declarations

Ethics approval and consent to participate

The ethics committee of Xinjiang Medical University Affiliated First Hospital approved this research. All patients provided written informed consent to participate.

Consent for publication

This manuscript has not been published or presented elsewhere in part or in entirety and is not under consideration by another journal. All authors agree to the publication of this work.

Competing interests

The authors declare no competing interests.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ting-Ting Wu and Ying Pan contributed equally to this work.
==== Refs
References

1. Mills KT Stefanescu A He J The global epidemiology of hypertension[J] Nat Rev Nephrol 2020 16 4 223 37 10.1038/s41581-019-0244-2 32024986
Mills KT, Stefanescu A, He J. The global epidemiology of hypertension[J]. Nat Rev Nephrol. 2020;16(4):223–37.32024986 10.1038/s41581-019-0244-2
2. Murray CJL Aravkin AY Zheng P Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the global burden of Disease Study 2019[J] Lancet 2020 396 10258 1223 49 10.1016/S0140-6736(20)30752-2 33069327
Murray CJL, Aravkin AY, Zheng P, et al. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the global burden of Disease Study 2019[J]. Lancet. 2020;396(10258):1223–49.33069327 10.1016/S0140-6736(20)30752-2
3. Mills KT Bundy JD Kelly TN Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries[J] Circulation 2016 134 6 441 50 10.1161/CIRCULATIONAHA.115.018912 27502908
Mills KT, Bundy JD, Kelly TN, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries[J]. Circulation. 2016;134(6):441–50.27502908 10.1161/CIRCULATIONAHA.115.018912
4. Ettehad D Emdin CA Kiran A Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis[J] Lancet 2016 387 10022 957 67 10.1016/S0140-6736(15)01225-8 26724178
Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis[J]. Lancet. 2016;387(10022):957–67.26724178 10.1016/S0140-6736(15)01225-8
5. Vongpatanasin W Management of hypertension in patients with coronary artery disease[J] Curr Hypertens Rep 2008 10 5 349 54 10.1007/s11906-008-0066-2 18775110
Vongpatanasin W. Management of hypertension in patients with coronary artery disease[J]. Curr Hypertens Rep. 2008;10(5):349–54.18775110 10.1007/s11906-008-0066-2
6. Frayn KN Coppack SW Insulin resistance, adipose tissue and coronary heart disease[J] Clin Sci 1992 82 1 1 8 10.1042/cs0820001
Frayn KN, Coppack SW. Insulin resistance, adipose tissue and coronary heart disease[J]. Clin Sci. 1992;82(1):1–8.10.1042/cs0820001
7. Henderson GC Plasma free fatty acid concentration as a modifiable risk factor for metabolic disease[J] Nutrients 2021 13 8 2590 10.3390/nu13082590 34444750
Henderson GC. Plasma free fatty acid concentration as a modifiable risk factor for metabolic disease[J]. Nutrients. 2021;13(8):2590.34444750 10.3390/nu13082590
8. Kumar V Xin X Ma J Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis[J] Adv Drug Deliv Rev 2021 176 113888 10.1016/j.addr.2021.113888 34314787
Kumar V, Xin X, Ma J, et al. Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis[J]. Adv Drug Deliv Rev. 2021;176:113888.34314787 10.1016/j.addr.2021.113888
9. Hierons SJ Marsh JS Wu D The interplay between non-esterified fatty acids and plasma zinc and its influence on thrombotic risk in obesity and type 2 diabetes[J] Int J Mol Sci 2021 22 18 10140 10.3390/ijms221810140 34576303
Hierons SJ, Marsh JS, Wu D, et al. The interplay between non-esterified fatty acids and plasma zinc and its influence on thrombotic risk in obesity and type 2 diabetes[J]. Int J Mol Sci. 2021;22(18):10140.34576303 10.3390/ijms221810140
10. Martchenko A Brubaker PL Effects of obesogenic feeding and free fatty acids on circadian secretion of metabolic hormones: implications for the development of type 2 diabetes[J] Cells 2021 10 9 2297 10.3390/cells10092297 34571945
Martchenko A, Brubaker PL. Effects of obesogenic feeding and free fatty acids on circadian secretion of metabolic hormones: implications for the development of type 2 diabetes[J]. Cells. 2021;10(9):2297.34571945 10.3390/cells10092297
11. Yuan D, Xu N, Song Y et al. Association between free fatty acids and cardiometabolic risk in coronary artery disease: results from the PROMISE Study[J]. J Clin Endocrinol Metabolism, 2023: dgad416.
12. Jin JL Cao YX Liu HH Impact of free fatty acids on prognosis in coronary artery disease patients under different glucose metabolism status[J] Cardiovasc Diabetol 2019 18 1 9 10.1186/s12933-019-0936-8 30626440
Jin JL, Cao YX, Liu HH, et al. Impact of free fatty acids on prognosis in coronary artery disease patients under different glucose metabolism status[J]. Cardiovasc Diabetol. 2019;18:1–9.30626440 10.1186/s12933-019-0936-8
13. Aline Charles M Fontbonne A Thibult N High plasma nonesterified fatty acids are predictive of cancer mortality but not of coronary heart disease mortality: results from the Paris prospective Study[J] Am J Epidemiol 2001 153 3 292 8 10.1093/aje/153.3.292 11157417
Aline Charles M, Fontbonne A, Thibult N, et al. High plasma nonesterified fatty acids are predictive of cancer mortality but not of coronary heart disease mortality: results from the Paris prospective Study[J]. Am J Epidemiol. 2001;153(3):292–8.11157417 10.1093/aje/153.3.292
14. Pilz S Scharnagl H Tiran B Free fatty acids are independently associated with all-cause and cardiovascular mortality in subjects with coronary artery disease[J] J Clin Endocrinol Metabolism 2006 91 7 2542 7 10.1210/jc.2006-0195
Pilz S, Scharnagl H, Tiran B, et al. Free fatty acids are independently associated with all-cause and cardiovascular mortality in subjects with coronary artery disease[J]. J Clin Endocrinol Metabolism. 2006;91(7):2542–7.10.1210/jc.2006-0195
15. Pilz S Scharnagl H Tiran B Elevated plasma free fatty acids predict sudden cardiac death: a 6.85-year follow-up of 3315 patients after coronary angiography[J] Eur Heart J 2007 28 22 2763 9 10.1093/eurheartj/ehm343 17766282
Pilz S, Scharnagl H, Tiran B, et al. Elevated plasma free fatty acids predict sudden cardiac death: a 6.85-year follow-up of 3315 patients after coronary angiography[J]. Eur Heart J. 2007;28(22):2763–9.17766282 10.1093/eurheartj/ehm343
16. Pan Y Wu TT Mao XF Decreased free fatty acid levels associated with adverse clinical outcomes in coronary artery disease patients with type 2 diabetes: findings from the PRACTICE study[J] Eur J Prev Cardiol 2023 30 8 730 9 10.1093/eurjpc/zwad073 36912007
Pan Y, Wu TT, Mao XF, et al. Decreased free fatty acid levels associated with adverse clinical outcomes in coronary artery disease patients with type 2 diabetes: findings from the PRACTICE study[J]. Eur J Prev Cardiol. 2023;30(8):730–9.36912007 10.1093/eurjpc/zwad073
17. Williams B Mancia G Spiering W 2018 ESC/ESH guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH)[J] Eur Heart J 2018 39 33 3021 104 10.1093/eurheartj/ehy339 30165516
Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH)[J]. Eur Heart J. 2018;39(33):3021–104.30165516 10.1093/eurheartj/ehy339
18. Nathan DM Diabetes: advances in diagnosis and treatment[J] JAMA 2015 314 10 1052 62 10.1001/jama.2015.9536 26348754
Nathan DM. Diabetes: advances in diagnosis and treatment[J]. JAMA. 2015;314(10):1052–62.26348754 10.1001/jama.2015.9536
19. Bartolomaeus H Balogh A Yakoub M Short-chain fatty acid propionate protects from hypertensive cardiovascular damage[J] Circulation 2019 139 11 1407 21 10.1161/CIRCULATIONAHA.118.036652 30586752
Bartolomaeus H, Balogh A, Yakoub M, et al. Short-chain fatty acid propionate protects from hypertensive cardiovascular damage[J]. Circulation. 2019;139(11):1407–21.30586752 10.1161/CIRCULATIONAHA.118.036652
20. Liu HH Cao YX Jin JL Lipoprotein (a), hypertension, and cardiovascular outcomes: a prospective study of patients with stable coronary artery disease[J] Hypertens Res 2021 44 9 1158 67 10.1038/s41440-021-00668-4 34035483
Liu HH, Cao YX, Jin JL, et al. Lipoprotein (a), hypertension, and cardiovascular outcomes: a prospective study of patients with stable coronary artery disease[J]. Hypertens Res. 2021;44(9):1158–67.34035483 10.1038/s41440-021-00668-4
21. Shieh SM Shen M Fuh MMT Plasma lipid and lipoprotein concentrations in Chinese males with coronary artery disease, with and without hypertension[J] Atherosclerosis 1987 67 1 49 55 10.1016/0021-9150(87)90264-4 3675705
Shieh SM, Shen M, Fuh MMT, et al. Plasma lipid and lipoprotein concentrations in Chinese males with coronary artery disease, with and without hypertension[J]. Atherosclerosis. 1987;67(1):49–55.3675705 10.1016/0021-9150(87)90264-4
22. Hennes MM I, O’Shaughnessy IM Kelly TM Insulin-resistant lipolysis in abdominally obese hypertensive individuals: role of the renin-angiotensin system[J] Hypertension 1996 28 1 120 6 10.1161/01.HYP.28.1.120 8675251
Hennes MM, I, O’Shaughnessy IM, Kelly TM, et al. Insulin-resistant lipolysis in abdominally obese hypertensive individuals: role of the renin-angiotensin system[J]. Hypertension. 1996;28(1):120–6.8675251 10.1161/01.HYP.28.1.120
23. Bm E Obesity hypertension is relate more to insulin’s fatty acid than glucose action[J] Hypertension 1996 27 723 8 10.1161/01.HYP.27.3.723 8613231
Bm E. Obesity hypertension is relate more to insulin’s fatty acid than glucose action[J]. Hypertension. 1996;27:723–8.8613231 10.1161/01.HYP.27.3.723
24. Fagot-Campagna A Balkau B Simon D High free fatty acid concentration: an independent risk factor for hypertension in the Paris prospective Study[J] Int J Epidemiol 1998 27 5 808 13 10.1093/ije/27.5.808 9839737
Fagot-Campagna A, Balkau B, Simon D, et al. High free fatty acid concentration: an independent risk factor for hypertension in the Paris prospective Study[J]. Int J Epidemiol. 1998;27(5):808–13.9839737 10.1093/ije/27.5.808
25. Tabara Y Takahashi Y Kawaguchi T Association of serum–free fatty acid level with reduced reflection pressure wave magnitude and central blood pressure: the Nagahama study[J] Hypertension 2014 64 6 1212 8 10.1161/HYPERTENSIONAHA.114.04277 25201894
Tabara Y, Takahashi Y, Kawaguchi T, et al. Association of serum–free fatty acid level with reduced reflection pressure wave magnitude and central blood pressure: the Nagahama study[J]. Hypertension. 2014;64(6):1212–8.25201894 10.1161/HYPERTENSIONAHA.114.04277
26. Weber T Auer J O’Rourke MF Arterial stiffness, wave reflections, and the risk of coronary artery disease[J] Circulation 2004 109 2 184 9 10.1161/01.CIR.0000105767.94169.E3 14662706
Weber T, Auer J, O’Rourke MF, et al. Arterial stiffness, wave reflections, and the risk of coronary artery disease[J]. Circulation. 2004;109(2):184–9.14662706 10.1161/01.CIR.0000105767.94169.E3
27. Nürnberger J Keflioglu-Scheiber A Saez AMO Augmentation index is associated with cardiovascular risk[J] J Hypertens 2002 20 12 2407 14 10.1097/00004872-200212000-00020 12473865
Nürnberger J, Keflioglu-Scheiber A, Saez AMO, et al. Augmentation index is associated with cardiovascular risk[J]. J Hypertens. 2002;20(12):2407–14.12473865 10.1097/00004872-200212000-00020
28. Spiller S Blüher M Hoffmann R Plasma levels of free fatty acids correlate with type 2 diabetes mellitus[J] Diabetes Obes Metabolism 2018 20 11 2661 9 10.1111/dom.13449
Spiller S, Blüher M, Hoffmann R. Plasma levels of free fatty acids correlate with type 2 diabetes mellitus[J]. Diabetes Obes Metabolism. 2018;20(11):2661–9.10.1111/dom.13449
29. Ragheb R Shanab GML Medhat AM Free fatty acid-induced muscle insulin resistance and glucose uptake dysfunction: evidence for PKC activation and oxidative stress-activated signaling pathways[J] Biochem Biophys Res Commun 2009 389 2 211 6 10.1016/j.bbrc.2009.08.106 19706288
Ragheb R, Shanab GML, Medhat AM, et al. Free fatty acid-induced muscle insulin resistance and glucose uptake dysfunction: evidence for PKC activation and oxidative stress-activated signaling pathways[J]. Biochem Biophys Res Commun. 2009;389(2):211–6.19706288 10.1016/j.bbrc.2009.08.106
30. Pereira S Park E Mori Y FFA-induced hepatic insulin resistance in vivo is mediated by PKCδ, NADPH oxidase, and oxidative stress[J] Am J Physiology-Endocrinology Metabolism 2014 307 1 E34 46 10.1152/ajpendo.00436.2013
Pereira S, Park E, Mori Y, et al. FFA-induced hepatic insulin resistance in vivo is mediated by PKCδ, NADPH oxidase, and oxidative stress[J]. Am J Physiology-Endocrinology Metabolism. 2014;307(1):E34–46.10.1152/ajpendo.00436.2013
31. Stefanovski D Punjabi NM Boston RC Insulin action, glucose homeostasis and free fatty acid metabolism: insights from a novel model[J] Front Endocrinol 2021 12 625701 10.3389/fendo.2021.625701
Stefanovski D, Punjabi NM, Boston RC, et al. Insulin action, glucose homeostasis and free fatty acid metabolism: insights from a novel model[J]. Front Endocrinol. 2021;12:625701.10.3389/fendo.2021.625701
32. Gerich JE. Contributions of insulin-resistance and insulin-secretory defects to the pathogenesis of type 2 diabetes mellitus[C]//Mayo Clinic Proceedings. Elsevier, 2003, 78(4): 447–456.
33. Porte D Jr Clinical importance of insulin secretion and its interaction with insulin resistance in the treatment of type 2 diabetes mellitus and its complications[J] Diab/Metab Res Rev 2001 17 3 181 8 10.1002/1520-7560(200105/06)17:3<181::AID-DMRR197>3.0.CO;2-1
Porte D Jr. Clinical importance of insulin secretion and its interaction with insulin resistance in the treatment of type 2 diabetes mellitus and its complications[J]. Diab/Metab Res Rev. 2001;17(3):181–8.10.1002/1520-7560(200105/06)17:3<181::AID-DMRR197>3.0.CO;2-1
34. da Silva AA do Carmo JM Li X Role of hyperinsulinemia and insulin resistance in hypertension: metabolic syndrome revisited[J] Can J Cardiol 2020 36 5 671 82 10.1016/j.cjca.2020.02.066 32389340
da Silva AA, do Carmo JM, Li X, et al. Role of hyperinsulinemia and insulin resistance in hypertension: metabolic syndrome revisited[J]. Can J Cardiol. 2020;36(5):671–82.32389340 10.1016/j.cjca.2020.02.066
35. Azekoshi Y Yasu T Watanabe S Free fatty acid causes leukocyte activation and resultant endothelial dysfunction through enhanced angiotensin II production in mononuclear and polymorphonuclear cells[J] Hypertension 2010 56 1 136 42 10.1161/HYPERTENSIONAHA.110.153056 20530293
Azekoshi Y, Yasu T, Watanabe S, et al. Free fatty acid causes leukocyte activation and resultant endothelial dysfunction through enhanced angiotensin II production in mononuclear and polymorphonuclear cells[J]. Hypertension. 2010;56(1):136–42.20530293 10.1161/HYPERTENSIONAHA.110.153056
36. Myers MA, McPhail LC, Snyderman R. Redistribution of protein kinase C activity in human monocytes: correlation with activation of the respiratory burst[J]. Journal of immunology (Baltimore, Md.: 1950), 1985, 135(5): 3411–3416.
37. Doctrow SR Folkman J Protein kinase C activators suppress stimulation of capillary endothelial cell growth by angiogenic endothelial mitogens[J] J Cell Biol 1987 104 3 679 87 10.1083/jcb.104.3.679 3469205
Doctrow SR, Folkman J. Protein kinase C activators suppress stimulation of capillary endothelial cell growth by angiogenic endothelial mitogens[J]. J Cell Biol. 1987;104(3):679–87.3469205 10.1083/jcb.104.3.679
38. Osol G, Laher I, Cipolla M. Protein kinase C modulates basal myogenic tone in resistance arteries from the cerebral circulation[J]. Circulation research, Cecelja M, Keehn L, Ye L et al. Genetic aetiology of blood pressure relates to aortic stiffness with bi-directional causality: evidence from heritability, blood pressure polymorphisms, and Mendelian randomization[J]. European Heart Journal, 2020, 41(35): 3314-3322z.
39. Xuereb RA Magri CJ Xuereb RG Arterial stiffness and its impact on cardiovascular health[J] Curr Cardiol Rep 2023 25 10 1337 49 10.1007/s11886-023-01951-1 37676581
Xuereb RA, Magri CJ, Xuereb RG. Arterial stiffness and its impact on cardiovascular health[J]. Curr Cardiol Rep. 2023;25(10):1337–49.37676581 10.1007/s11886-023-01951-1
40. Watanabe S, Tagawa T, Yamakawa K et al. Inhibition of the renin-angiotensin system prevents free fatty acid–induced acute endothelial dysfunction in humans[J]. Arteriosclerosis, thrombosis, and vascular biology, 2005, 25(11): 2376–80.
41. Maison P Byrne CD Hales CN Hypertension and its treatment influence changes in fasting nonesterified fatty acid concentrations: a link between the sympathetic nervous system and the metabolic syndrome?[J] Metabolism 2000 49 1 81 7 10.1016/S0026-0495(00)90788-1 10647068
Maison P, Byrne CD, Hales CN, et al. Hypertension and its treatment influence changes in fasting nonesterified fatty acid concentrations: a link between the sympathetic nervous system and the metabolic syndrome?[J]. Metabolism. 2000;49(1):81–7.10647068 10.1016/S0026-0495(00)90788-1
42. Brenner C Galluzzi L Kepp O Decoding cell death signals in liver inflammation[J] J Hepatol 2013 59 3 583 94 10.1016/j.jhep.2013.03.033 23567086
Brenner C, Galluzzi L, Kepp O, et al. Decoding cell death signals in liver inflammation[J]. J Hepatol. 2013;59(3):583–94.23567086 10.1016/j.jhep.2013.03.033
43. Ramadori P Kroy D Streetz KL Immunoregulation by lipids during the development of non-alcoholic steatohepatitis[J] Hepatobiliary Surg Nutr 2015 4 1 11 25713801
Ramadori P, Kroy D, Streetz KL. Immunoregulation by lipids during the development of non-alcoholic steatohepatitis[J]. Hepatobiliary Surg Nutr. 2015;4(1):11.25713801
44. Lipke K Kubis-Kubiak A Piwowar A Molecular mechanism of lipotoxicity as an interesting aspect in the development of pathological states—current view of knowledge[J] Cells 2022 11 5 844 10.3390/cells11050844 35269467
Lipke K, Kubis-Kubiak A, Piwowar A. Molecular mechanism of lipotoxicity as an interesting aspect in the development of pathological states—current view of knowledge[J]. Cells. 2022;11(5):844.35269467 10.3390/cells11050844
